This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1
by Zacks Equity Research
Conatus, (CNAT) earnings and revenues lag estimates in the first-quarter of 2019. Emricasan remains in focus.
Gilead (GILD) Earnings Beat, Revenues Miss Estimates in Q1
by Zacks Equity Research
Biotech bigwig Gilead's (GILD) Q1 financial report is mixed with dismal sales and an earnings beat.
Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down
by Zacks Equity Research
Ligand (LGND) first-quarter earnings and sales decrease year over year.
PDL BioPharma (PDLI) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During PDL BioPharma's (PDLI) Q1 conference call, investor focus will be on the company's ability to acquire new income-generating assets for frequent revenue growth.
Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
While Incyte's (INCY) earnings and revenues beat estimates in Q1, Jakafi sales fall short of the same.
Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings?
by Zacks Equity Research
Incyte (INCY) is slated to report first-quarter results on Apr 30. Investors will primarily focus on Jakafi sales and pipeline updates.
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Strong sales of Glaxo's (GSK) Vaccines segment is likely to drive the top line in the first quarter.
Novartis (NVS) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Novartis (NVS) beats on Q1 earnings, sales marginally miss estimates.
Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs
by Zacks Equity Research
Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.
Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran
by Zacks Equity Research
Alnylam (ALNY) initiates phase III study on lumasiran and also reports new positive efficacy results from the ongoing phase II open-label extension (OLE) study on the same.
Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales
by Zacks Equity Research
Radius Health's (RDUS) lead drug, Tymlos, gains traction in 2018. Let us see how the drug will fare in 2019 amid increasing competition.
Marijuana ETF Down 9% in Past Month: Time to Enter the Space?
by Sanghamitra Saha
Growing global acceptance, increasing legalization and beaten-down prices open up room for marijuana ETF investing.
Allergan Falls as Supreme Court Dismisses Restasis Litigation
by Zacks Equity Research
Allergan's (AGN) key drug, Restasis' prospects hurt as the U.S. Supreme Court upholds the ruling of a lower court, which invalidated certain patents protecting the drug.
Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA
by Zacks Equity Research
The FDA accepts Novartis' (NVS) BLA seeking approval for brolucizumab for the treatment of wet AMD.
Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran
by Zacks Equity Research
Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic porphyria.
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
by Kinjel Shah
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Ophthotech Gets Rights to Gene Therapy for BEST Disease
by Zacks Equity Research
Ophthotech (OPHT) obtains development/commercialization rights to AAV gene-therapy program for BEST1-related retinal diseases from Penn and UFRF.
Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon
by Zacks Equity Research
Novartis' (NVS) Sandoz signs an agreement with Japanese company, Shionogi, to commercialize constipation drug in key European markets.
Biotechnology Market on a Tear: 5 ETFs in Spotlight
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
Intercept Reports Additional Positive Data From NASH Study
by Zacks Equity Research
Intercept Pharmaceuticals (ICPT) reports positive additional supportive data from its phase III REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH.
Top Research Reports for McDonald's, Enterprise Products & Charles Schwab
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including McDonald's (MCD), Enterprise Products Partners (EPD) and Charles Schwab (SCHW).
Amgen's (AMGN) Osteoporosis Drug Evenity Gets FDA Approval
by Zacks Equity Research
Amgen (AMGN) gets approval in the United States for osteoporosis drug, Evenity.
Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. The company's efforts to expand the drug's label also hold promise and bode well for long-term growth.
The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men
by Kinjel Shah
Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.